• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 表达联合微卫星不稳定性/CD8+肿瘤浸润淋巴细胞作为胃癌有价值的预后生物标志物。

PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.

机构信息

Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.

出版信息

Sci Rep. 2019 Mar 15;9(1):4633. doi: 10.1038/s41598-019-41177-2.

DOI:10.1038/s41598-019-41177-2
PMID:30874607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6420501/
Abstract

While the importance of programmed death-ligand 1 (PD-L1), mutation burden caused by microsatellite instability (MSI), and CD8+ tumor infiltrating lymphocytes (TILs) has become evident, the significance of PD-L1 expression on prognosis still remains controversial. We evaluated the usefulness of combined markers of PD-L1 and MSI or CD8+ TILs as a prognostic biomarker in gastric cancer. A total of 283 patients with gastric cancer were reviewed retrospectively. PD-L1 expression on >5% tumor cells was defined as PD-L1-positive. PD-L1-positive rate was 15.5% (44/283). PD-L1 positivity was significantly correlated with invasive and advanced cancer and also significantly correlated with MSI, whereas no significance was observed with CD8+ TILs. Kaplan-Meier analysis showed that PD-L1 positivity significantly correlated with a poor prognosis (p = 0.0025). Multivariate analysis revealed that PD-L1 positivity was an independent poor prognostic factor (hazard ratio [HR]: 1.97, p = 0.0106) along with diffuse histological type and lymph node metastases. Combinations of PD-L1 and MSI (HR: 2.18) or CD8+ TILs (HR: 2.57) were stronger predictive factors for prognosis than PD-L1 alone. In conclusion, combined markers of PD-L1 and MSI or CD8+ TILs may be more useful prognostic biomarkers in gastric cancer, and better clarify the immune status of gastric cancer patients.

摘要

虽然程序性死亡配体 1(PD-L1)、由微卫星不稳定性(MSI)引起的突变负担和 CD8+肿瘤浸润淋巴细胞(TIL)的重要性已经很明显,但 PD-L1 表达对预后的意义仍存在争议。我们评估了 PD-L1 和 MSI 或 CD8+TIL 联合标志物作为胃癌预后生物标志物的有用性。回顾性分析了 283 例胃癌患者。将>5%肿瘤细胞上的 PD-L1 表达定义为 PD-L1 阳性。PD-L1 阳性率为 15.5%(44/283)。PD-L1 阳性与侵袭性和晚期癌症显著相关,也与 MSI 显著相关,而与 CD8+TIL 无显著相关性。Kaplan-Meier 分析显示,PD-L1 阳性与预后不良显著相关(p=0.0025)。多因素分析显示,PD-L1 阳性是独立的预后不良因素(风险比[HR]:1.97,p=0.0106),与弥漫性组织学类型和淋巴结转移有关。PD-L1 与 MSI(HR:2.18)或 CD8+TIL(HR:2.57)的组合是比 PD-L1 单独预测预后的更强的因素。总之,PD-L1 和 MSI 或 CD8+TIL 的联合标志物可能是胃癌更有用的预后生物标志物,可以更好地阐明胃癌患者的免疫状态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/89cc61e2c35d/41598_2019_41177_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/80890508b3d3/41598_2019_41177_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/d3d9d28eb346/41598_2019_41177_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/0bff32101504/41598_2019_41177_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/89cc61e2c35d/41598_2019_41177_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/80890508b3d3/41598_2019_41177_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/d3d9d28eb346/41598_2019_41177_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/0bff32101504/41598_2019_41177_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6452/6420501/89cc61e2c35d/41598_2019_41177_Fig4_HTML.jpg

相似文献

1
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.PD-L1 表达联合微卫星不稳定性/CD8+肿瘤浸润淋巴细胞作为胃癌有价值的预后生物标志物。
Sci Rep. 2019 Mar 15;9(1):4633. doi: 10.1038/s41598-019-41177-2.
2
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.胃腺癌中 PD-L1 联合肿瘤浸润淋巴细胞、EB 病毒和微卫星不稳定性的预后预测。
Diagn Pathol. 2020 Jun 4;15(1):69. doi: 10.1186/s13000-020-00979-z.
3
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.II期和III期胃癌患者中基于PD-L1表达和CD8阳性肿瘤浸润淋巴细胞的免疫分类的临床病理意义
Oncotarget. 2017 Apr 18;8(16):26356-26367. doi: 10.18632/oncotarget.15465.
4
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.程序性死亡配体1表达在与爱泼斯坦-巴尔病毒或微卫星不稳定性相关的胃癌中很常见。
Am J Surg Pathol. 2016 Nov;40(11):1496-1506. doi: 10.1097/PAS.0000000000000698.
5
Prognostic value of PD-L1 expression in combination with CD8 TILs density in patients with surgically resected non-small cell lung cancer.PD-L1 表达联合 CD8 TIL 密度对手术切除的非小细胞肺癌患者的预后价值。
Cancer Med. 2018 Jan;7(1):32-45. doi: 10.1002/cam4.1243. Epub 2017 Nov 23.
6
Differential prognostic impact of CD8 T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer.基于人类白细胞抗原 I 和 PD-L1 表达的 CD8 T 细胞在微卫星不稳定型胃癌中的预后差异影响。
Br J Cancer. 2020 Apr;122(9):1399-1408. doi: 10.1038/s41416-020-0793-y. Epub 2020 Mar 17.
7
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.肿瘤 PD-L1 表达联合 CD8 肿瘤浸润淋巴细胞对高级别浆液性卵巢癌的预后价值。
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.
8
High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.程序性细胞死亡蛋白1(PD-1)(+)/ CD8(+)肿瘤浸润淋巴细胞比例高,可识别接受手术加辅助放化疗的肝外胆管癌预后不良亚组。
Radiother Oncol. 2015 Oct;117(1):165-70. doi: 10.1016/j.radonc.2015.07.003. Epub 2015 Jul 30.
9
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.PD-L1表达和CD8 + T细胞浸润在肺神经内分泌肿瘤中的预后意义
Diagn Pathol. 2018 May 22;13(1):30. doi: 10.1186/s13000-018-0712-1.
10
The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.PD-1、PD-L1表达及CD3+ T细胞浸润与晚期胃印戒细胞癌预后的关系,是免疫治疗的潜在生物标志物。
Oncotarget. 2017 Jun 13;8(24):38850-38862. doi: 10.18632/oncotarget.16407.

引用本文的文献

1
Isolated tumor cell clusters (ITC) in lymph nodes and PD-L1 expression on tumor-associated immune cells are prognostic factors for microsatellite instable-high gastric cancers.淋巴结中的孤立肿瘤细胞簇(ITC)以及肿瘤相关免疫细胞上的PD-L1表达是微卫星高度不稳定型胃癌的预后因素。
Transl Oncol. 2025 Sep;59:102465. doi: 10.1016/j.tranon.2025.102465. Epub 2025 Jul 1.
2
Bibliometric analysis of tumor marker application in gastric cancer diagnosis from 2019 to 2024.2019年至2024年胃癌诊断中肿瘤标志物应用的文献计量分析
Front Med (Lausanne). 2025 May 7;12:1547850. doi: 10.3389/fmed.2025.1547850. eCollection 2025.
3

本文引用的文献

1
Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.胃腺癌中 PD-L1、吲哚胺 2,3-双加氧酶的表达及免疫微环境。
Histopathology. 2018 Jul;73(1):124-136. doi: 10.1111/his.13504. Epub 2018 Apr 17.
2
Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.四种单核苷酸重复标记物在鉴定实体瘤中 DNA 错配修复缺陷的准确性。
J Transl Med. 2018 Jan 12;16(1):5. doi: 10.1186/s12967-017-1376-4.
3
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
The artificial intelligence revolution in gastric cancer management: clinical applications.
胃癌管理中的人工智能革命:临床应用
Cancer Cell Int. 2025 Mar 21;25(1):111. doi: 10.1186/s12935-025-03756-4.
4
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法:克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
5
upregulates the immune inhibitory receptor in colorectal cancer cells via the activation of ALPK1.通过激活ALPK1上调结肠癌细胞中的免疫抑制受体。
Gut Microbes. 2025 Dec;17(1):2458203. doi: 10.1080/19490976.2025.2458203. Epub 2025 Jan 29.
6
The microenvironment cell index is a novel indicator for the prognosis and therapeutic regimen selection of cancers.微环境细胞指数是一种用于癌症预后和治疗方案选择的新型指标。
J Transl Med. 2025 Jan 13;23(1):61. doi: 10.1186/s12967-024-05950-w.
7
Construction of ferroptosis and pyroptosis model to assess the prognosis of gastric cancer patients based on bioinformatics.基于生物信息学构建铁死亡和细胞焦亡模型以评估胃癌患者的预后
Transl Cancer Res. 2024 Nov 30;13(11):5751-5770. doi: 10.21037/tcr-24-683. Epub 2024 Nov 27.
8
Association between infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer.胃癌中感染、错配修复、人表皮生长因子受体2(HER2)与肿瘤浸润淋巴细胞之间的关联
World J Gastrointest Oncol. 2024 Jun 15;16(6):2487-2503. doi: 10.4251/wjgo.v16.i6.2487.
9
Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.基于生物标志物的晚期胃癌靶向治疗及免疫检查点抑制剂的研究进展与展望
Front Oncol. 2024 Jun 14;14:1382183. doi: 10.3389/fonc.2024.1382183. eCollection 2024.
10
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.胆管癌中微卫星不稳定高的基因组特征和免疫治疗。
BMC Med. 2024 Jan 29;22(1):42. doi: 10.1186/s12916-024-03257-7.
美国食品药品监督管理局首次批准与癌症部位无关——当生物标志物确定适应症时。
N Engl J Med. 2017 Oct 12;377(15):1409-1412. doi: 10.1056/NEJMp1709968.
4
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者(ONO-4538-12,ATTRACTION-2):一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
5
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis.肿瘤浸润淋巴细胞在胃癌中的预后作用:一项荟萃分析。
Oncotarget. 2017 May 22;8(34):57386-57398. doi: 10.18632/oncotarget.18065. eCollection 2017 Aug 22.
6
Targeting neoantigens to augment antitumour immunity.靶向新抗原以增强抗肿瘤免疫力。
Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74.
7
Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology.免疫时代胃癌肿瘤浸润淋巴细胞的临床意义
World J Gastrointest Oncol. 2017 Jul 15;9(7):293-299. doi: 10.4251/wjgo.v9.i7.293.
8
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.程序性死亡受体 1 配体(PD-L1)与胃癌预后:一项系统评价和荟萃分析。
PLoS One. 2017 Aug 10;12(8):e0182692. doi: 10.1371/journal.pone.0182692. eCollection 2017.
9
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.肿瘤细胞 PD-L1 表达阴性而免疫细胞 PD-L1 表达阳性是头颈部肿瘤患者的预后良好因素。
Sci Rep. 2016 Nov 14;6:36956. doi: 10.1038/srep36956.
10
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.